Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nektaria Dimopoulos

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Immunity|March 10, 2005
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccinationQiyuan Chen, Heather Jackson, Mark Shackleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 15, 2006
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patientsIan D Davis, Qiyuan Chen, Leone Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 16, 2004
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantQiyuan Chen, Heather Jackson, Phillip Parente, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Immunity|March 10, 2005
Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccinationQiyuan Chen, Heather Jackson, Mark Shackleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou, Lisa M Ebert, Ian D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4Oliver Klein, Lisa M Ebert, Theo Nicholaou, et al.
Cancer Immunology, Immunotherapy : CII|June 24, 2011
Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™Theo Nicholaou, Weisan Chen, Ian D Davis, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Plos One|September 13, 2012
A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigenRona Y Zhao, Nicole A Mifsud, Kun Xiao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 15, 2006
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patientsIan D Davis, Qiyuan Chen, Leone Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 16, 2004
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantQiyuan Chen, Heather Jackson, Phillip Parente, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Pageof 2